JP6879921B2 - システインプロテアーゼ - Google Patents

システインプロテアーゼ Download PDF

Info

Publication number
JP6879921B2
JP6879921B2 JP2017542900A JP2017542900A JP6879921B2 JP 6879921 B2 JP6879921 B2 JP 6879921B2 JP 2017542900 A JP2017542900 A JP 2017542900A JP 2017542900 A JP2017542900 A JP 2017542900A JP 6879921 B2 JP6879921 B2 JP 6879921B2
Authority
JP
Japan
Prior art keywords
ides
igg
polypeptide
seq
cleavage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017542900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510622A5 (enExample
JP2018510622A (ja
Inventor
チェルマン、クリスティアン
イャルヌム、ソフィア
ノルダル、エマ
Original Assignee
ハンサ バイオファーマ エービー
ハンサ バイオファーマ エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンサ バイオファーマ エービー, ハンサ バイオファーマ エービー filed Critical ハンサ バイオファーマ エービー
Publication of JP2018510622A publication Critical patent/JP2018510622A/ja
Publication of JP2018510622A5 publication Critical patent/JP2018510622A5/ja
Application granted granted Critical
Publication of JP6879921B2 publication Critical patent/JP6879921B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
JP2017542900A 2015-02-12 2016-02-12 システインプロテアーゼ Active JP6879921B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201502305A GB201502305D0 (en) 2015-02-12 2015-02-12 Protein
GB1502305.4 2015-02-12
PCT/EP2016/053054 WO2016128559A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (3)

Publication Number Publication Date
JP2018510622A JP2018510622A (ja) 2018-04-19
JP2018510622A5 JP2018510622A5 (enExample) 2019-03-28
JP6879921B2 true JP6879921B2 (ja) 2021-06-02

Family

ID=52781455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542900A Active JP6879921B2 (ja) 2015-02-12 2016-02-12 システインプロテアーゼ

Country Status (28)

Country Link
US (3) US10758597B2 (enExample)
EP (2) EP4265719A1 (enExample)
JP (1) JP6879921B2 (enExample)
KR (1) KR102524594B1 (enExample)
CN (2) CN113564150B (enExample)
AU (1) AU2016217801B2 (enExample)
BR (1) BR112017017286A2 (enExample)
CA (1) CA2976016C (enExample)
CL (1) CL2017002066A1 (enExample)
CO (1) CO2017009060A2 (enExample)
DK (1) DK3256579T5 (enExample)
EA (1) EA035896B1 (enExample)
ES (1) ES2962794T3 (enExample)
FI (1) FI3256579T3 (enExample)
GB (1) GB201502305D0 (enExample)
HR (1) HRP20231496T1 (enExample)
HU (1) HUE064122T2 (enExample)
IL (1) IL253939B (enExample)
LT (1) LT3256579T (enExample)
MX (1) MX391632B (enExample)
MY (1) MY187486A (enExample)
PL (1) PL3256579T3 (enExample)
PT (1) PT3256579T (enExample)
RS (1) RS64840B1 (enExample)
SG (1) SG11201706349YA (enExample)
SI (1) SI3256579T1 (enExample)
WO (1) WO2016128559A1 (enExample)
ZA (1) ZA201705114B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN108410798A (zh) * 2018-03-27 2018-08-17 福建三造血技术有限公司 细胞分离用微珠洗脱液及配制方法
MX2020010464A (es) 2018-04-03 2021-01-29 Vectores de virus que evitan anticuerpos.
US12116384B2 (en) 2018-04-03 2024-10-15 Ginkgo Bioworks, Inc. Virus vectors for targeting ophthalmic tissues
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2020159970A1 (en) * 2019-01-28 2020-08-06 Duke University Compositions and methods for evading humoral immunity
AU2020241888A1 (en) 2019-03-21 2021-09-30 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors
DE102019112558A1 (de) 2019-05-14 2020-11-19 Claas Selbstfahrende Erntemaschinen Gmbh Verfahren zur Wartung und/oder Reparatur einer landwirtschaftlichen Arbeitsmaschine
US20220347298A1 (en) 2019-10-04 2022-11-03 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ，インコーポレイテッド ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
AU2020396490C1 (en) 2019-12-06 2023-04-27 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
IL294558A (en) * 2020-01-22 2022-09-01 Spark Therapeutics Inc Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
CN115151648A (zh) 2020-02-14 2022-10-04 阿尔特拉吉尼克斯制药公司 用于治疗cdkl5缺陷障碍的基因疗法
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
JP7795790B2 (ja) 2020-06-05 2026-01-08 上海宝済薬業股▲ふん▼有限公司 酵素とウィルスとの薬物組成物及びその使用
JP2023532219A (ja) * 2020-06-18 2023-07-27 上海宝済薬業有限公司 免疫グロブリン分解酵素ＩｄｅＥの突然変異体
BR112023003145A2 (pt) 2020-08-19 2023-05-09 Sarepta Therapeutics Inc Vetores de vírus adenoassociado para tratamento da síndrome de rett
US20230374083A1 (en) * 2020-09-21 2023-11-23 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical combination and use thereof
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
AU2022256479A1 (en) 2021-04-16 2023-11-30 AskBio Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
FR3125965B1 (fr) * 2021-08-05 2024-06-21 Mc Saf Conjugués anticorps-médicament
US20250019721A1 (en) 2021-08-11 2025-01-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
US20250325640A1 (en) 2021-11-15 2025-10-23 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
KR20240123827A (ko) 2021-12-16 2024-08-14 상하이 바오 파마슈티컬스 컴퍼니 리미티드 항면역글로불린 분해 효소에 의해 효소 절단된 Fc 변이체
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
WO2024057095A1 (en) 2022-09-14 2024-03-21 Genovis Ab Mutant protease
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN118853710A (zh) * 2022-11-08 2024-10-29 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
EP4619443A2 (en) 2022-11-18 2025-09-24 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
US12129499B2 (en) 2023-01-06 2024-10-29 Seismic Therapeutic, Inc. Protease variants and uses thereof
CN121263202A (zh) * 2023-03-29 2026-01-02 赛勒斯生物科技股份有限公司 IdeS变体蛋白及其使用方法
WO2025103235A1 (zh) * 2023-11-13 2025-05-22 上海宝济药业股份有限公司 一种免疫球蛋白降解酶IdeE的突变体
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes
CN118497176B (zh) * 2024-07-16 2025-01-21 苏州康聚生物科技有限公司 一种免疫球蛋白降解酶

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
WO1997015592A1 (en) * 1995-10-23 1997-05-01 Incyte Pharmaceuticals, Inc. Novel human cysteine protease
CA2421278A1 (en) * 1998-03-11 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
AU2002216863B8 (en) 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
WO2006131347A2 (en) 2005-06-09 2006-12-14 Hansa Medical Ab Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
EP2190984B1 (en) 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
CN102026658A (zh) * 2007-12-13 2011-04-20 英特瓦克公司 改进的免疫组合物
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
JP5461586B2 (ja) 2009-02-09 2014-04-02 ロシュ グリクアート アクチェンゲゼルシャフト 免疫グロブリングリコシル化パターン分析
CA2799136A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins

Also Published As

Publication number Publication date
EA035896B1 (ru) 2020-08-27
IL253939A0 (en) 2017-10-31
CN113564150B (zh) 2024-09-17
EP3256579B1 (en) 2023-08-30
SI3256579T1 (sl) 2024-01-31
BR112017017286A2 (pt) 2018-04-17
AU2016217801B2 (en) 2022-03-17
NZ733962A (en) 2024-07-05
GB201502305D0 (en) 2015-04-01
KR102524594B1 (ko) 2023-04-21
ZA201705114B (en) 2024-01-31
EP4265719A1 (en) 2023-10-25
CL2017002066A1 (es) 2018-02-02
HRP20231496T1 (hr) 2024-03-01
AU2016217801A1 (en) 2017-08-10
JP2018510622A (ja) 2018-04-19
CN107532158A (zh) 2018-01-02
EP3256579A1 (en) 2017-12-20
US20180037962A1 (en) 2018-02-08
MY187486A (en) 2021-09-24
KR20170110153A (ko) 2017-10-10
DK3256579T5 (en) 2024-10-14
PT3256579T (pt) 2023-11-23
US11524057B2 (en) 2022-12-13
US10758597B2 (en) 2020-09-01
IL253939B (en) 2020-01-30
CN113564150A (zh) 2021-10-29
CA2976016C (en) 2023-08-29
ES2962794T3 (es) 2024-03-21
DK3256579T3 (en) 2023-11-20
RS64840B1 (sr) 2023-12-29
US20200179497A1 (en) 2020-06-11
SG11201706349YA (en) 2017-09-28
MX391632B (es) 2025-03-21
CO2017009060A2 (es) 2018-01-16
PL3256579T3 (pl) 2024-02-26
WO2016128559A1 (en) 2016-08-18
US20230302100A1 (en) 2023-09-28
HUE064122T2 (hu) 2024-03-28
EA201791775A1 (ru) 2018-02-28
CA2976016A1 (en) 2016-08-18
LT3256579T (lt) 2023-11-27
FI3256579T3 (fi) 2023-11-13
MX2017010389A (es) 2017-12-07

Similar Documents

Publication Publication Date Title
JP6879921B2 (ja) システインプロテアーゼ
JP6961486B2 (ja) システインプロテアーゼ
JP7770341B2 (ja) システインプロテアーゼ
EA049939B1 (ru) Цистеин-протеаза
HK1240611B (en) Cysteine protease
HK1240611A1 (en) Cysteine protease
HK1240619B (en) Cysteine protease
HK1240619A1 (en) Cysteine protease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171024

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210430

R150 Certificate of patent or registration of utility model

Ref document number: 6879921

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250